Theratechnologies Shareholders Approve Arrangement with CB Biotechnology.

Theratechnologies shareholders have approved the previously announced plan of arrangement with CB Biotechnology, LLC, an affiliate of Future Pak. The arrangement was approved by 97.44% of votes cast by shareholders present in person or virtually or represented by proxy. The deal involves the acquisition of Theratechnologies by Future Pak.

Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, has announced that its shareholders have overwhelmingly approved the previously announced plan of arrangement to be acquired by Future Pak affiliate CB Biotechnology, LLC. The arrangement resolution received strong support with 97.44% approval from shareholders present or represented by proxy, and 97.43% approval from minority shareholders. The transaction's completion remains subject to customary closing conditions, including final approval from the Superior Court of Québec, with a hearing scheduled for September 16, 2025.

The acquisition plan, which was approved at a special meeting of shareholders, involves CB Biotechnology, LLC, an affiliate of Future Pak, LLC. The proposed arrangement is subject to certain customary closing conditions, including the issuance of a final order by the Superior Court of Québec following a hearing expected to take place on September 16, 2025.

Theratechnologies is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Future Pak, founded in 1977, is a privately held contract manufacturer, packager, and distributor of pharmaceutical and nutraceutical products. The acquisition is expected to enhance Theratechnologies' capabilities and position it for future growth.

The approval of the arrangement is a significant step forward for Theratechnologies, but it is important to note that the deal remains subject to regulatory approvals and other customary closing conditions. Investors should closely monitor the progress of the transaction and be aware of the potential risks and uncertainties associated with the acquisition.

For further information, please contact:
- Theratechnologies Inc.
- Investor inquiries: Philippe Dubuc, Senior Vice President and Chief Financial Officer, pdubuc@theratech.com, 438-315-6608
- Media inquiries: Julie Schneiderman, Senior Director, Communications & Corporate Affairs, communications@theratech.com, 514-336-7800